The endosomal compartment of hepatic parenchymal cells contains an acidic endopeptidase, endosomal acidic insulinase, which hydrolyzes internalized insulin and generates the major primary end product A 1-21 -B 1-24 insulin resulting from a major cleavage at residues Phe B24 -Phe B25 . This study addresses the nature of the relevant endopeptidase activity in rat liver that is responsible for most receptor-mediated insulin degradation in vivo. The endosomal activity was shown to be aspartic acid protease cathepsin D (CD), based on biochemical similarities to purified CD in 1) the rate and site of substrate cleavage, 2) pH optimum, 3) sensitivity to pepstatin A, and 4) binding to pepstatin A-agarose. The identity of the protease was immunologically confirmed by removal of greater than 90% of the insulindegrading activity associated with an endosomal lysate using polyclonal antibodies to CD. Moreover, the elution profile of the endosomal acidic insulinase activity on a gel-filtration TSK-GEL G3000 SW XL high performance liquid chromatography column corresponded exactly with the elution profile of the immunoreactive 45-kDa mature form of endosomal CD. Using nondenaturating immunoprecipitation and immunoblotting procedures, other endosomal aspartic acid proteases such as cathepsin E and ␤-site amyloid precursor protein-cleaving enzyme (BACE) were ruled out as candidate enzymes for the endosomal degradation of internalized insulin. Immunofluorescence studies showed a largely vesicular staining pattern for internalized insulin in rat hepatocytes that colocalized partially with CD. In vivo pepstatin A treatment was without any observable effect on the insulin receptor content of endosomes but augmented the phosphotyrosine content of the endosomal insulin receptor after insulin injection. These results suggest that CD is the endosomal acidic insulinase activity which catalyzes the rate-limiting step of the in vivo cleavage at the Phe B24 -Phe B25 bond, generating the inactive A 1-21 -B 1-24 insulin intermediate.
The endosomal compartment of hepatic parenchymal cells contains an acidic endopeptidase, endosomal acidic insulinase, which hydrolyzes internalized insulin and generates the major primary end product A 1-21 -B
1-24
insulin resulting from a major cleavage at residues Phe B24 -Phe B25 . This study addresses the nature of the relevant endopeptidase activity in rat liver that is responsible for most receptor-mediated insulin degradation in vivo. The endosomal activity was shown to be aspartic acid protease cathepsin D (CD), based on biochemical similarities to purified CD in 1) the rate and site of substrate cleavage, 2) pH optimum, 3) sensitivity to pepstatin A, and 4) binding to pepstatin A-agarose. The identity of the protease was immunologically confirmed by removal of greater than 90% of the insulindegrading activity associated with an endosomal lysate using polyclonal antibodies to CD. Moreover, the elution profile of the endosomal acidic insulinase activity on a gel-filtration TSK-GEL G3000 SW XL high performance liquid chromatography column corresponded exactly with the elution profile of the immunoreactive 45-kDa mature form of endosomal CD. Using nondenaturating immunoprecipitation and immunoblotting procedures, other endosomal aspartic acid proteases such as cathepsin E and ␤-site amyloid precursor protein-cleaving enzyme (BACE) were ruled out as candidate enzymes for the endosomal degradation of internalized insulin. Immunofluorescence studies showed a largely vesicular staining pattern for internalized insulin in rat hepatocytes that colocalized partially with CD. In vivo pepstatin A treatment was without any observable effect on the insulin receptor content of endosomes but augmented the phosphotyrosine content of the endosomal insulin receptor after insulin injection. These results suggest that CD is the endosomal acidic insulinase activity which catalyzes the rate-limiting step of the in vivo cleavage at the Phe B24 -Phe B25 bond, generating the inactive A 1-21 -B 1-24 insulin intermediate.
Proteins entering the endocytic pathway encounter an increasingly hydrolytic environment imposed by a progressive decrease in pH and an increase in protease concentrations (reviewed in Ref. 1) . Ultimately, most are degraded in lysosomes to small peptides and free amino acids. For some, degradation takes place early in the endocytic pathway. This is the case for polypeptide hormones such as insulin (2) (3) (4) , glucagon (5) , and parathyroid hormone (6) and growth factors such as the epidermal growth factor (7) and insulin-like growth factor-I (IGF-I) 1 (8) as well as endocytosed protein antigens for major histocompatibility class II presentation (9) and plant toxins (10) .
In liver parenchyma the endosomal degradation of internalized insulin is thought to occur after acidification of the endosomal lumen by a soluble enzyme termed endosomal acidic insulinase (EAI) (2, 3, 11) , although this protease has yet to be identified. EAI, which was easily extracted by hypotonic shock from hepatic endosomes, displayed an acidic pH optimum for insulin binding and degradation (2, 3, 11) . The events leading to the endosomal proteolysis of internalized insulin by EAI involve initial binding of the C-terminal region of the B chain of insulin to EAI followed by two initial proteolytic cleavages at Phe B24 -Phe B25 and Phe B25 -Tyr B26 peptide bonds (11) . This is followed by the hydrolysis of seven peptide bonds in the C terminus of the insulin B chain and, in the central region of the insulin A and B chains, via an ordered sequential pathway. The high IC 50 value of insulin for EAI (2-4 ϫ 10 Ϫ5 M) and the high proteolytic activity and affinity of EAI for insulin B chain and a B [22] [23] [24] [25] [26] [27] [28] [29] [30] insulin fragment suggest that EAI is a nonspecific peptidase whose physiological substrates other than insulin within the endosomal apparatus have yet to be defined (11) . In support of this, we have recently demonstrated that cathepsin B, a general cysteine protease, down-regulates internalized epidermal growth factor and glucagon within rat liver endosomes (5, 7) and internalized IGF-I in MCF-7 and H-59 tumor cells (8) by inducing proteolytic cleavages of these ligands.
Previous attempts to purify and identify EAI have been made using the radiolabeled peptide [ 125 I-Tyr A14 ]insulin to measure endosomal hydrolysis of insulin by monitoring the increase in soluble counts after precipitation of radioactive insulin with cold trichloroacetic acid (2, 3) . Based on the trichloroacetic acid precipitation assay, endosomal proteolysis of [ 125 I-Tyr A14 ]insulin was partially inhibited by chelating agents, thiol reagents, pepstatin A, leupeptin, and bacitracin (2) . However, none of the protease inhibitors was individually capable of completely inhibiting [ 125 I-Tyr A14 ]insulin proteolysis, suggesting the contribution of more than one protease to the processing of radioactive insulin. Later, using an alternate approach based on reverse-phase (RP) HPLC and mass spectrometry analysis in which hydrolysis was measured by the * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.generation of degradation products from unlabeled HI, we elucidated the entire structure of nine early insulin intermediates generated within hepatic endosomes, all of which contained the A 14 tyrosine residue in their sequence and displayed a molecular mass higher than 3125 Da (11) . Indeed, all of the early insulin intermediates identified in this study were not trichloroacetic acid-soluble (11) . Consequently, the trichloroacetic acid solubility of radioactive products, which greatly underestimates actual degradation, reflects additional and/or further processing of transient insulin intermediates and their late transformation into short end products and/or free amino acids by endosomal proteases that are possibly distinct from EAI.
These concerns were addressed in this study by using native HI as the substrate and RP HPLC to improve the specificity of the degradation assay and identify the nature of EAI. An early time point of HI digestion was always chosen for RP HPLC analysis, when the two primary products A (12, 13) , rabbit anti-rat cathepsin B 7183 (5, 7, 14) , and rabbit anti-rat cathepsin L R958 (5, 15) were obtained from Dr. J. S. Mort (Shriners Hospital for Crippled Children, Montreal, Quebec) and used to immune-deplete samples of native mature enzymes as described previously (5, 7) . Rabbit polyclonal antisera directed against N-and C-terminal ␤-site amyloid precursor protein-cleaving enzyme (BACE) peptides were obtained from Dr. R. W. Doms (University of Pennsylvania School of Medicine, Philadelphia, PA) and have been described previously (16) . Affinity-purified goat antibody raised against human cathepsin E (sc-6508), which cross-reacts with cathepsin E of rat origin, was purchased from Santa Cruz Biotechnology Inc. Mouse monoclonal antibody 9B12 directed against the human insulin-degrading enzyme (17) was a kind gift from Dr. R. A. Roth (Stanford University, Stanford, CA). Polyclonal IgG against the human insulin receptor ␤-subunit and mouse monoclonal anti-phosphotyrosine (clone 4G10) were purchased from Upstate Biotechnology Inc. Mouse monoclonal antibody directed against the rat early endosome antigen 1 (EEA1) was purchased from Transduction Laboratories. Horseradish peroxidase-conjugated goat anti-rabbit IgG and goat anti-mouse IgG were from Bio-Rad. The protein content of isolated fractions was determined by the method of Lowry et al. (18) . N-Acetyl-␤-D-glucosaminidase was assayed with pnitrophenyl N-acetyl-␤-D-glucosaminide as substrate according to Touster et al. (19) . Acid phosphatase was assayed as described by Trouet (20) . Nitrocellulose membranes and the Enhanced Chemiluminescence (ECL) detection kit were from Amersham Biosciences, Inc. Protein G-Sepharose was from Amersham Biosciences, Inc. CA074, which is a highly selective irreversible cathepsin B inhibitor, was purchased from Peptides International. Pepstatin A, pepstatin A-agarose, EDTA, 1,10-phenanthroline, E64, N-ethylmaleimide, p-hydroxymercuri phenylsulfonic acid, iodoacetamide, phenylmethylsulfonyl fluoride, and benzamidine were from Sigma. HPLC grade acetonitrile and trifluoroacetic acid were obtained from J. T. Baker Inc. All other chemicals were obtained from commercial sources and were of reagent grade.
Animals and Injections-Male Sprague-Dawley rats, body weight 180 -200 g, were obtained from Charles River France (St. Aubin Les Elbeufs, France) and were fasted for 18 h before sacrifice. Native insulin (15 g/100 g of body weight) in 0.4 ml of 0.15 M NaCl was injected within 5 s into the penis vein under light anesthesia with ether. In some experiments, rats received an intraperitoneal injection of 2 mg of pepstatin A in 0.4 ml of 12.5% Me 2 SO, 0.15 M NaCl 1 h before HI injection.
Isolation of Subcellular Fractions from Rat Liver-Subcellular fractionation was performed using established procedures (2, 3, 5, 7, 11, (21) (22) (23) . After injection of human insulin, animals were sacrificed, and livers were rapidly removed and minced in isotonic ice-cold homogenization buffer as previously described (2, 3, 5, 7, 11, 21-23).
Lysosomes were prepared by isopycnic centrifugation of the light mitochondrial fraction in a discontinuous metrizamide gradient according to the method of Wattiaux et al. (24) . Lysosomes (L2 fraction) were collected at the 1.109 -1.135 g/ml metrizamide interface (24) . The endosomal fraction was isolated by discontinuous sucrose gradient centrifugation and collected at the 0.25-1.0 M sucrose interface (2, 3, 5, 7, 11, (21) (22) (23) . The soluble extract from the endosomal fractions was isolated by freeze/thawing in 5 mM sodium phosphate, pH 7.4, and disrupted in the same hypotonic medium using a small Dounce homogenizer (15 strokes with Type A pestle) followed by centrifugation at 300,000 ϫ g av for 30 min as described previously (2, 3, 5, 7, 11, 25) .
Endosomal fractions isolated after the injection of HI were suspended at 1.5 mg/ml in 62.5 mM Tris/HCl, pH 6.8, 2% SDS, 10% glycerol, 2% ␤-mercaptoethanol and heated at 100°C for 2 min. Samples were then subjected to SDS-PAGE, followed by Western blotting to determine the integrity and phosphotyrosine content of the internalized insulin receptor.
Immunoblot Analysis-Electrophoresed samples were transferred to nitrocellulose membranes (0.45 ϫ 10 Ϫ6 m) for 60 min at 380 mA in transfer buffer containing 25 mM Tris base and 192 mM glycine. The membranes were blocked by a 3-h incubation with 5% skim milk or 2% bovine serum albumin (for phosphotyrosine immunoblots) in 10 mM Tris-HCl, pH 7.5, 300 mM NaCl, and 0.05% Tween 20. The membranes were then incubated with primary antibody (rabbit polyclonal antisera against either mouse cathepsin D R291 diluted 1:1500, human BACE diluted 1:1000 or rat cathepsin L R958 diluted 1:200, affinity-purified polyclonal antibodies to insulin receptor diluted 1:1000, monoclonal anti-phosphotyrosine diluted 1:2500) in the above buffer for 16 h at 4°C. After incubation, the blots were washed 3 times with 0.5% skim milk or 0.2% bovine serum albumin (for phosphotyrosine immunoblots) in 10 mM Tris-HCl, pH 7.5, 300 mM NaCl, and 0.05% Tween 20 over a period of 1 h at room temperature. The bound immunoglobulin was detected using horseradish peroxidase-conjugated goat anti-rabbit IgG for the polyclonal antibody or horseradish peroxidase-conjugated goat anti-mouse IgG for the monoclonal anti-phosphotyrosine antibody.
In Vitro Proteolysis of Native Peptides-Soluble endosomal extract (ENs) (Ϸ1 ng) was incubated for varying lengths of time at 37°C with 5 ϫ 10 Ϫ5 M human insulin, insulin A chain, or insulin B chain in 200 ϫ 10 Ϫ6 liters of 50 mM citrate-phosphate, pH 4, in the presence or absence of protease inhibitors. The samples were then acidified with acetic acid (15%) and immediately loaded onto a RP HPLC column. In some experiments, ENs was immunodepleted of active insulin-degrading enzyme, cathepsin L, cathepsin B, or cathepsin D before the digestion step by incubating ENs (0.15 mg/ml) with antibodies coated to protein GSepharose for 16 h at 4°C in 800 ϫ 10 Ϫ6 liters of 20 mM sodium phosphate buffer, pH 7. The fractions were then centrifuged for 5 min at 10,000 ϫ g av, and the resultant supernatants were adjusted to pH 4 with citrate-phosphate buffer and used in the HI degradation assay. The reaction was terminated by the addition of 15% acetic acid and immediately assayed by RP HPLC .
Native HI, insulin A chain, and insulin B chain were also digested in vitro with bovine cathepsin D. Insulin peptides (5 ϫ 10 Ϫ5 M) were incubated with 0.025 units/ml cathepsin D in 0.1 M citrate-phosphate, pH 4. After 5-60 min of incubation at 37°C, the proteolytic reaction was stopped by adding acetic acid (15%), and the samples were immediately analyzed by RP HPLC.
HPLC Separation of Human Insulin, Insulin A Chain, and Insulin B Chain Peptides-RP HPLC was performed on a Beckman Coulter System Gold model 127 liquid chromatograph equipped with a Rheodyne sample injector fitted with a 500-l loop and a microBondapak C18 column (Waters, 0.39 ϫ 30 cm; 10 Ϫ5 m particle size). Samples were chromatographed using a mixture of 0.1% trifluoroacetic acid in water (solvent A) and 0.1% trifluoroacetic acid in acetonitrile (solvent B) with a flow rate of 1 ml/min. Elution was carried out using two sequential linear gradients of 0 -15% solvent B (5 min) and 15-39% solvent B (32 min) followed by an isocratic elution of 39% solvent B (13 min). Eluates were monitored on-line for absorbance at 214 nm with a LC-166 spectrophotometer (Beckman Coulter).
Binding of Endosomal Acidic Insulinase to Pepstatin A-agaroseENs (0.15 mg/ml) was incubated for 15 h at 4°C with pepstatin Aagarose in 20 mM citrate-phosphate buffer, pH 7. After centrifugation at 20,000 ϫ g av for 5 min, the resultant supernatant was tested for its ability to degrade 10 Ϫ6 M HI in 300 mM citrate-phosphate buffer, pH 4, at 37°C for varying amounts of time, and samples were immediately analyzed by RP HPLC.
Characterization of Endosomal Acidic Insulinase Using Gel-filtration HPLC-ENs was loaded onto a TSK-GEL G3000 SW XL HPLC column (Tosoh Corp., 0.78 ϫ 30 cm) equilibrated at 4°C with 50 mM sodium phosphate buffer, pH 6. The column was washed with 30 ml of sodium phosphate buffer, pH 6, using a flow rate of 0.5 ml/min. Eluates were monitored on-line for absorbance at 214 nm with an LC-166 spectrophotometer (Beckman Coulter). Each fraction (0.5 ml) was immediately adjusted to pH 4 with 0.5 M citrate-phosphate buffer and evaluated for insulin-degrading activity by incubating with 5 ϫ 10 Ϫ5 M HI at 37°C for 10 min. The reaction was stopped by the addition of 15% acetic acid, and samples were analyzed by RP HPLC or subjected to SDS-PAGE followed by Western blotting to determine their cathepsin D content. In some experiments, fractions eluted from the gel-filtration HPLC column that contained insulin-degrading activity with the highest specific activity (fraction 20; see Fig. 4A ) were incubated for 15 h at 4°C with pepstatin A-agarose in 75 mM citrate-phosphate buffer, pH 7. After centrifugation at 20,000 ϫ g av for 5 min, the bound proteins were subjected to SDS-PAGE and Western blot analysis.
Mass Spectrometry-Samples were prepared and analyzed using ion spray mass spectrometry and HPLC electron spray ionization mass spectrometry coupling as previously described (11) .
Hepatocyte Culture-Primary hepatocytes were isolated from male Sprague-Dawley rats weighing 180 -200 g. Hepatocytes were prepared by collagenase perfusion and purified by Percoll gradient centrifugation (26) as modified by Balavoine et al. (27) . Viability was Ͼ85% by trypan blue exclusion. Hepatocytes were suspended in William's E medium (Invitrogen) supplemented with 10% fetal bovine serum, 1% penicillin/ streptomycin, and 1% glutamine and plated on type-I collagen-coated glass coverslips.
Immunofluorescence-Hepatocytes grown on glass coverslips were washed once with phosphate-buffered saline (PBS) before incubation with serum-free William's E medium containing 2 M human insulin. After 20 min at 37°C, cells were washed 3 times with PBS and fixed with 3% paraformaldehyde in PBS for 20 min. Fixed cells were treated with 100 mM NH 4 Cl for 15 min, washed with PBS, permeabilized with 0.1% Triton X-100 in PBS for 4 min, and blocked by a 20-min incubation with 10% horse serum in PBS. Staining consisted of mouse monoclonal antibody to human insulin (diluted 1:100) (Sigma), mouse monoclonal antibody to rat EEA1 (diluted 1:200) (Transduction Laboratories), and rabbit polyclonal antibody to mouse cathepsin D R291 (diluted 1:100) as the primary reagents, followed by Alexa Fluor 488-conjugated goat anti-mouse (diluted 1:100) (Molecular Probes) and Texas Red-conjugated goat anti-rabbit (diluted 1:400) (Jackson Immunoresearch). Laser-scanning confocal microscopy was done with a Zeiss LSM 510 confocal (Axiovert 100 M) inverted microscope equipped with a Zeiss X63/ 1.4 NA oil immersion objective lens (plan-Apochromat). Fluorescent images were acquired with argon (wavelength 488 nm) and helium neon (wavelength 543 nm) lasers. Simultaneous images corresponding to Alexa Fluor 488 and Texas Red fluorescence were obtained using the multi-tracking function of the microscope.
RESULTS

Catalytic Properties of Endosomal Acidic
Insulinase-As a substrate, radiolabeled HI may lack many structural features of the natural EAI substrate that might be important in directing protease interaction and cleavage. Moreover, the trichloroacetic acid precipitation assay gives only limited information about the enzymatic mechanism of insulin degradation where conditions are far from the initial reaction rate. The most appropriate substrate for assaying EAI activity is native HI, which contains the physiological prerequisites for protease recognition. We therefore decided to reevaluate the effect of various protease inhibitors on the insulin-degrading activity contained in endosomes using a highly specific RP HPLC assay ( Fig. 1) . A short time of digestion was always chosen in order to follow the major primary cleavage of HI at residues Phe B24 -Phe B25 , which generates the hexapeptide B [25] [26] [27] [28] [29] [30] (Fig. 1B , middle panel, peak 2) and the remaining N-terminal residues B connected to the intact A chain A 
mM benzamidine (panel A).
At the end of the incubation, the proteolytic reaction was stopped with acetic acid (15%), and the incubation mixtures were analyzed by RP HPLC as described under "Experimental Procedures." The rate of HI proteolysis was determined by following the disappearance of the peak area corresponding to the parent peptide. The results are expressed as HI degraded (% of control) and normalized to that seen in the absence of added compound. The results are the mean Ϯ S.D. of three to five different experiments performed on endosomal fractions prepared from separate liver fractionations. Panel B shows representative RP HPLC profiles resulting from the incubation of HI with ENs in the presence or absence of 0.1 g/ml PA. All panels show absorbance profiles at 214 nm. Intact HI had an elution time of 48 min. The endosomal proteins alone did not give any detectable peak (results not shown). 4 and 37°C for 15 min in the presence of protease inhibitors (Fig. 1A) . The protease activity was strongly inhibited (Ͼ95%) by pepstatin A, an inhibitor of aspartic acid proteases (Fig. 1, A and B, lower panel). No effect was observed with metallo-, cysteine-, and serine-protease inhibitors (Fig. 1A) . From these results it was concluded that the primary cleavages of native HI were due to aspartic acid protease(s).
Identification of Aspartic Acid Proteases Associated with Hepatic Endosomes-Of the intracellular aspartic acid proteases characterized to date in mammalian cells, the most obvious candidates for our observed results are cathepsin D, cathepsin E, or BACE (28, 29) . We were unable to detect cathepsin E in hepatic endosomes by Western blot analysis (results not shown), confirming the little or no detectable expression of the protease previously reported in rat liver parenchyma (29) . ENs was then evaluated for its content of cathepsin D and BACE by immunoblotting with well characterized polyclonal antibodies ( Fig. 2) (5, 16) . The soluble hypotonic extract from endosomes (ENs) showed intense immunoreactivity for the 45-kDa mature cathepsin D enzyme and the 64-kDa cathepsin D proenzyme. By contrast, using anti-BACE antibodies directed against N-(␣-BACE N) and C-terminal (␣-BACE C) BACE peptides (16) , BACE immunoreactivity (68-kDa) was restricted to endosomal membranes (ENm) with none detectable in the luminal content (ENs), confirming that BACE is an integral membrane protein (30) .
The possibility of lysosome contamination of our endosomal fraction has been assessed in Fig. 3 . We compared enzyme distribution in endosomal and lysosomal fractions of two lysosomal enzyme markers, acid phosphatase and N-acetyl-␤-Dglucosaminidase (Fig. 3A) . The endosomal fraction revealed no significant enrichment of N-acetyl-␤-D-glucosaminidase (relative specific activity ϭ 1.5) and acid phosphatase (relative specific activity ϭ 2.2) with the yield of enzymes accounting for Ͻ0.2% that of homogenate. On the other hand, the L2 lysosomal fraction was more than 60 times enriched in lysosomal enzyme markers (Fig. 3A) . Overall, the enrichment of radiolabeled [
125 I]Tyr A14 human insulin in endosomal fractions at the early time (4 min) of endocytosis (relative specific activity ϭ 92.4 Ϯ 6.38) was far greater than that of any of the enzymes assayed (results not shown; Ref. 3) . As well, we used the well characterized anti-cathepsin antibodies to assess the distribution of precursor and mature forms of cathepsins in hepatic endosomes (EN) and lysosomes (L2) (Fig. 3B) . The 37-kDa procathepsin L and 64-kDa procathepsin D proenzymes were exclusively identified in endosomes, whereas lysosomes showed strong immunoreactivity only for mature cathepsin L (29-and 22-kDa species) and cathepsin D (45-and 31-kDa species). The distinct distribution of procathepsin L to endosomes and mature 29-kDa single-chain and 22-kDa heavy-chain cathepsin L to lysosomes attests to the lack of contamination of our endosomal fraction by lysosomes (Fig. 3B) . These data essentially agree with previously published studies (5, 21) .
Identification of Endosomal Acidic Insulinase as Cathepsin D-The aspartic acid proteolytic activity associated with soluble endosomal proteins that generates the major primary cleavage Phe B24 -Phe B25 after digestion of native HI was further purified on a TSK-GEL G3000 HPLC column (Fig. 4) . Fractions eluted from the gel-filtration HPLC column were characterized for their insulinase activity at pH 4 using native HI followed by RP HPLC (Fig. 4A) . In addition, fractions 13-25 were assayed for their content of cathepsin D by Western blotting using anti-cathepsin D antibody (Fig. 4B) . (Fig. 4B) .
To determine whether other endosomal proteases in addition to aspartic acid proteases may participate in the primary cleavage of the insulin B chain at the Phe B24 -Phe B25 peptide bond, ENs was incubated with pepstatin A-agarose at pH 7, and the absorbed proteins were precipitated by centrifugation (Fig. 5) . Analysis of the bead supernatant showed that depletion of pepstatin A-binding proteins prevented proteolysis of native HI as measured at pH 4 and 15 or 30 min of incubation (Fig. 5A ). To test whether pepstatin A-agarose bound nonspecifically to other endosomal proteins, we determined the protein concentration of the endosomal fractions before and after the pepstatin A-agarose precipitation step (Fig. 5B) , and we could not detect any significant change in protein concentration. To gain more information regarding the specificity of the insulinasepepstatin A interaction, the HPLC fraction from the TSK-GEL G3000 column with the highest acidic insulinase activity (fraction 20, see Fig. 4A ) was incubated with pepstatin A-agarose beads (Fig. 5C ). The bead precipitate was then subjected to SDS-PAGE and Western blotting using anti-mouse cathepsin D antibody (Fig. 5C, PA-ag pellet) , revealing the presence of the two active forms of cathepsin D at 45 and 31 kDa. Hence, the EAI activity present in ENs likely corresponds to an active form of cathepsin D.
As further evidence, we used well characterized polyclonal antibodies to mature cathepsin D and its proform (5) to deplete cathepsin D from ENs (Fig. 6) . Quantitative immunoprecipitation of cathepsin D using antibodies directed against the mouse and human enzyme removed greater than 90% of endosomal HI-degrading activity from ENs based on the Phe B24 -Phe B25 peptide bond cleavage assay at acidic pH (Fig. 6, A and B) .
Immunodepletion of ENs with antibodies to cathepsins L and B and insulin-degrading enzyme failed to remove the insulinase activity as measured at pH 4 ( Fig. 6A) .
Digestion of Insulin Peptides with Cathepsin D-
To determine whether cathepsin D is capable of cleaving HI at the same primary sites as those observed with ENs (11), HI was subjected to in vitro digestion with bovine cathepsin D at pH 4. The digestion products were separated by RP HPLC, and the resulting chromatogram is shown in Fig. 7 (lower panel, HI ϩ  CD) . RP HPLC analysis revealed four proteolytic products (peaks 1-4) with retention times identical to those seen with ENs (upper panel, HI ϩ ENs) (11). Each of the major HPLC peaks for HI plus CD was analyzed using mass spectrometry to determine the molecular masses of the peptide products. We have previously shown that the insulin B chain represents a high affinity substrate for EAI (11) . Using RP HPLC analysis of digestions performed under initial rate conditions, we have compared the rate of hydrolysis of intact HI and the individual insulin A and B chains by ENs or pure cathepsin D (Fig. 8) . As previously reported (11), ENs degraded insulin B chain more efficiently than for intact HI, whereas the rate of hydrolysis of insulin A chain was lower than that of HI ( ( Fig. 9 ). Hepatocytes were incubated with 2 ϫ 10 Ϫ6 M HI for 20 min, when most of the internalized ligand would be located in the endosomes (3), and the subcellular localization of both HI and cathepsin D were revealed by indirect immunofluorescence (Fig. 9A) . Antibody to HI (in green) demonstrated a highly punctate staining pattern reminiscent of vesicular compartments. Costaining with antibody directed against mature and precursor cathepsin D enzyme (in red) revealed a partial colocalization (in yellow) with the intracellular protease. HI colocalization did not overlap completely with intracellular cathepsin D, although the extent of signal overlap was quite significant (Fig. 9A) .
The localization of cathepsin D in endocytic vesicles was next examined by double-staining immunofluorescence with the early endosome marker EEA1 (Fig. 9B) . A partial immunoreactivity of cathepsin D was observed in the early endocytic vesicles identified by the presence of EEA1. These results confirm a minor but genuine endosomal location for the lysosomal aspartic acid protease. Moreover, the previous biochemical and morphological demonstrations that internalized insulin in hepatocytes accumulated into endocytic components clearly distinguishable from lysosomes (reviewed in Ref. 
Effect of Pepstatin A on the Fate of Insulin Receptor within Hepatic Endosomes in Vivo-
The level of insulin receptor internalization and the tyrosine phosphorylation state of the internalized insulin receptor could potentially be affected by pepstatin A, which affects endosomal proteolysis of HI. Therefore, the effect of pepstatin A on endosomal insulin receptor signal transduction was next examined (Fig. 10) . Animals were administered an intraperitoneal injection of either 12.5% Me 2 SO, 0.15 M NaCl or 2 mg of pepstatin A diluted in 12.5% Me 2 SO, 0.15 M NaCl 1 h before native HI administration, and animals were sacrificed 2-60 min after HI administration. Hepatic endosomes were prepared, and the amount of internalized insulin receptor and its phosphotyrosine content was determined by Western blot analyses. A time-dependent increase in insulin receptor content was observed in endosomal fractions isolated 2-30 min after administration of a single receptorsaturating dose of HI (15 g/100 g of body weight) as described previously (3) (Fig. 10, lower panel) . No difference in the time nor extent of receptor internalization was observed after pepstatin A treatment. In contrast, a difference was observed for tyrosine phosphorylation of the insulin receptor ␤-subunit. Insulin administration led to a brief burst (2 min) of tyrosine autophosphorylation of the insulin receptor, and pepstatin A treatment could extend this time to 5 min (Fig. 10, upper  panel) .
DISCUSSION
The soluble aspartic acid protease cathepsin D has been identified as the insulin-degrading activity responsible for the primary cleavages of internalized insulin within hepatic endosomes. In this study, we sought to characterize the proteolytic function of endosomal cathepsin D toward the insulin substrate through a series of biochemical and morphological investigations. Using similar approaches, we have previously reported that hepatic endosomes contain the cysteine protease cathepsin B, that processes internalized glucagon (5), epidermal growth factor (7), and IGF-I (8). Identically, we have recently shown that CA074-methyl ester, a cathepsin B inhibitor, prevented endosomal processing of internalized IGF-I in MCF-7 and H-59 tumor cells (8) . Consistent with our previous studies, we concluded in this present work that the EAI activity was likely the aspartic acid protease cathepsin D, as indicated by the following observations. (a) The inhibitor profile and the pH optimum of the endosomal proteolytic activity were similar to those of cathepsin D; (b) immunodepletion of cathepsin D from ENs led to a loss of EAI activity; (c) the EAI activity was specifically absorbed to pepstatin A-agarose; (d) Western blot experiments demonstrated the presence of the 45-kDa active form of cathepsin D as well as its 64-kDa inactive precursor in the endosomal lumen; (e) using confocal immunofluorescent microscopy, internalization of HI into rat hepatocytes led to partial colocalization of internalized insulin with cathepsin D and cathepsin D with the early endocytic marker EEA1; and (f) pure cathepsin D produced a cleavage pattern for HI that was similar to that generated using the endosomal proteolytic activity.
That the presence of active cathepsin D within hepatic endosomes was due to lysosomal contamination of our endosomal fraction is highly unlikely. Thus, the modest content of N-acetyl-␤-D-glucosaminidase and acid phosphatase in our endosomal fraction points to minimal contamination by lysosomes and confirms our earlier observations (21) . Moreover, mature lysosomal cathepsin L was undetectable in our endosomal fraction although its inactive precursor was easily identified. Finally, immunofluorescence studies performed on rat hepatocytes revealed that the endosomal marker protein EEA1 was present in some cathepsin D-positive structures, suggesting a genuine endosomal localization for the cathepsin D enzyme. These data conform well to previous biochemical (5, 32) and morphological evidence (33) that active cathepsin D was selectively retained within hepatic endosomes.
Although the radiolabeled peptide [ 125 I-Tyr A14 ]HI can be used to assay insulin degradation at the endosomal locus (2-4), caution should be used when interpreting this cleavage activity as the true EAI activity (11) . First, radioactive HI might not display all the primary, secondary, and tertiary structural elements of the natural peptide substrate (34) . Thus, the radioactive iodine on the molecule might mask the substrate recognition site and the sites of cleavage for the endosomal proteolytic system. Secondly, although a trichloroacetic acid precipitation assay has been developed for the degradation analysis of radioactive insulin (2-4, 11), the limitation of this type of assay is that it greatly underestimates actual degradation and measures the proteolytic activities under conditions far from the initial rate of the reaction. In a complex system where intermediate cleavage products can be further processed, it is difficult to obtain any meaningful information on the enzyme of interest. The trichloroacetic acid precipitation assay is, therefore, inherently unsuitable to screening for a specific protease in endosomal lysates, where many other proteases with a broad substrate specificity are likely to be present (5, 7) . Thus, we have developed an RP HPLC assay based on measurement of the initial degradation step of native HI by endosomal lysates, with the subsequent identification of the was treated in vitro with ENs or 0.025 units/ml cathepsin D in 0.1 M citrate-phosphate buffer, pH 4. After 15 min (HI ϩ ENs) or 60 min (HI ϩ CD) at 37°C, the proteolytic reaction was stopped by adding acetic acid (15%), and the hydrolysis products were immediately analyzed by RP HPLC. The major degradation products, pools 1-4, were collected from the elution profile HI ϩ CD as indicated. These pools were subjected to mass spectrometry analyses (see Table I ).
TABLE I
Masses and assigned structures of the cleavage products generated from human insulin by cathepsin D Selected HPLC pools (see Fig. 7 ) generated by bovine cathepsin D were analyzed by HPLC coupled with electron spray ionization-mass spectrometry. Average molecular masses are used for calculations. HPLC pools 2 and 4 are heterogeneous. HPLC pools 1 and 2 are the carboxyl end of the B chain. HPLC pools 3, 4a, and 4b are portions of the amino end of the B chain still connected by disulfide bonds to intact A chain. HPLC pool 4c is intact human insulin. HPLC After 5-120 min at 37°C, the proteolytic reaction was stopped by adding acetic acid (15%), and the incubation mixture was analyzed by RP HPLC. The rate of hydrolysis of each peptide was determined by following the disappearance of the peak area, corresponding to the parent peptide. The results are the mean Ϯ S.D. of three different experiments performed on endosomal fractions prepared from separate liver fractionations.
early insulin intermediates. The improved specificity of this method allowed for the rigorous screening of EAI activity. However, we cannot exclude that very late cleavages of small insulin intermediates observed within hepatic endosomes (11) may be produced by other endosomal endo-and/or exopeptidases such as cathepsin B (5, 7), insulin-degrading enzyme (35) , or other as yet unidentified endosomal proteolytic activities.
Despite the limitations of the trichloroacetic acid precipitation assay, an accurate examination of the early proteolytic cleavages generated in vivo has been possible with the use of monoiodinated insulin isomers combined with RP HPLC and radiosequencing procedures (35) (36) (37) (38) . Using this approach, endosome-associated degradation products extracted at an early time of insulin endocytosis displayed intact A chain and cleavages in the B chain at B 24 bonds (35) (36) (37) (38) . Structural and kinetic analyses of in vivo intermediates isolated from the intraendosomal compartment have allowed the determination of an ordered sequence involving an initial cleavage in the B chain at 24 -25, which produces des(hexapeptide)insulin (38) . This process has been supported by our in vitro study characterizing endosomal proteolysis of native HI using a soluble endosomal extract from rat liver parenchyma (11) . This study showed initial B 24 -B 25 cleavage with the parallel production of des(hexapeptide)-HI and the C-terminal B chain hexapeptide (B [25] [26] [27] [28] [29] [30] ) (11) . Therefore, we elected to pursue the in vitro characterization of EAI using the most sensitive assay for insulin degradation by following the primary in vivo cleavage between Phe B24 and Phe B25 residues.
The two primary end products of HI that are generated using cell-free endosomes (this study; Ref. 11) and pure cathepsin D (this study) result from proteolytic cleavages occurring at residues Phe B24 -Phe B25 (major pathway) and Phe B25 -Tyr B26 (minor pathway), two sites that fit the specificity pattern for sites cleaved by cathepsin D (39) . Sequences readily cleaved by cathepsin D contain apolar or hydrophobic residues situated on both sides of the cleavage site, with the Phe-Phe bond strongly favored and, in most cases, a hydrophobic residue in position P 1 (39) . Thus, the sites in HI that were cleaved to produce the two primary end products A (11) and cleavage (8) of the insulin-related IGF-I polypeptide by EAI activity and aspartic acid proteases were not detected upon incubation of this growth factor with hepatic ENs and tumor cell lysates. One explanation might be the difference in primary sequence between positions B 24 -B 26 (Phe-Phe-Tyr) of the insulin B chain and the corresponding positions 23-25 (Phe-Tyr-Phe) of IGF-I, which displays a simple inversion of the insulin Phe-Tyr sequence and lacks the unique Phe-Phe bond (45) .
The present studies indicate that internalized insulin is a physiological substrate for the endosomal protease cathepsin D. Cathepsin D has been identified in endosomes of rabbit alveolar macrophages by biosynthetic studies and affinity chromatography purification (46) , in hepatic endosomes by Western blotting (5, 32) and immunocytochemistry (33) , in multivesicular endosomes of macrophages (47) and B-lymphoblastoid cells (48) by immunocytochemistry, and in the late endosomal Rab7-containing compartment by flow cytometric sorting (49) . Consistent with previous studies on the subcellular distribution and molecular species of cathepsins in liver parenchyma (5, 32) and other studies on the biogenesis of cathepsin D (46, 49, 50) , the cathepsin D species identified in endosomes consisted of both the inactive precursor and active mature forms. These data suggest that significant processing of lysosomal hydrolases may occur within endosomes (46) . The molecular mechanisms responsible for targeting and retaining cathepsin D and its proform in endosomes are not clear. Morphological and biochemical analyses, which focused on the localization and targeting of the cation-independent mannose 6-phosphate receptor (CI-MPR) in stable BHK cell lines and one of its ligands, cathepsin D, have shown that a significant fraction of CI-MPR and cathepsin D traffic from the trans-Golgi network to late endosomes/lysosomes via early endosomes (51) . Alternatively, mannose 6-phosphate receptor-independent membrane associ- ation of cathepsin D has been reported within acidic endosomes in macrophages (46) , in HepG2 cells (50) , in human B-lymphocytes (52) , and in NIH 3T3 mouse fibroblasts (53) .
In the present study, we provide also the first evidence for endosomal compartmentalization of the recently identified ␤-secretase protein BACE in hepatocytes. By immunoblot analysis, we confirmed earlier biochemical and immunofluorescence studies that had localized BACE to endosomes, one of several intracellular sites where amyloid ␤ is thought to be produced (28) . The accumulation of BACE in the endosomal system appears to be governed largely by a cytoplasmic dileucine motif (16) . Although the evidence is quite compelling that BACE is the ␤-secretase in Alzheimer's disease (16, 28, 30) , it has not been established whether other soluble or membrane-bound proteins, related or not to ␤-amyloid precursor protein, are subject to endosomal cleavage by BACE. The previously reported transmembrane property of BACE (30), confirmed by us in this study, provides evidence against a role for BACE in the proteolysis of free insulin within the endosomal lumen. However, the type-I integral membrane protein BACE may be a good candidate protease for the endosomal degradation of membrane-associated peptides.
Our present work combined with our previous studies that provided the first evidence for endosomal compartmentalization of cathepsin B in hepatocytes (5, 7) is in total agreement with other studies suggesting that 20 -40% of newly synthesized lysosomal hydrolases can be detected in early endosomes (54) . Recently, cell fractionation studies performed on stable BHK cell lines reveal cathepsin D comigration with Rab5 and EEA1, established markers of early endosomes, as well as the sensitivity of cathepsin D to horseradish peroxidase/diaminobenzidine-mediated cross-linking of endosomal proteins (51) . Our immunofluorescence studies confirm that a small amount of cathepsin D can be detected in early endocytic EEA1-positive vesicles. In the study of Press et al. (51) , the potential significance of cathepsin D delivery to early endosomes is discussed in light of its involvement in cellular growth control and differentiation. Indeed, increased extracellular levels of various cathepsins, especially cathepsins D and B, have been correlated to metastasis and a number of human tumors (55) . Thus, endosomal cathepsin D may modulate the amount of these molecules delivered to the cell surface versus the amount transported toward lysosomes (51) . Even cell death was recently shown to be influenced by endosomal/lysosomal cathepsin D in a study showing its involvement in cell apoptosis induced by oxidative stress (56) . Our studies provide important clues regarding another function of endosomal cathepsin D related to the proteolysis of internalized ligands, with the subsequent regulation of intracellular receptor signaling and trafficking at the endosomal locus (1, 3, 5) .
Cathepsin D induces the proteolytic cleavage of several other polypeptide hormones, proteins, and plant toxins within endocytic vesicles. Thus, we have previously reported that internalized glucagon is partially processed within hepatic endosomes by the endopeptidase activity of cathepsin D (5). Also, proteolysis of mannose-bovine serum albumin and parathyroid hormone-(1-84), with the subsequent release of the bioactive peptide parathyroid hormone-(1-34), was primarily mediated by cathepsin D within macrophage endosomes (6) . The participation of cathepsin D in the endosomal processing, membrane translocation, and cytotoxicity of ricin A chain has also been demonstrated (10) . Studies have also suggested the potential role of cathepsin D in conjunction with cathepsins S and L in degrading the invariant chain and endocytosed antigens within antigen-presenting cells (57) . Finally, some properties associated with cathepsin D favor its putative role in the amyloidogenic processing of ␤-amyloid precursor protein within the endo-lysosomal compartment (43, 58) .
In this study, we have shown that in vivo administration of pepstatin A, a compound that inhibits endosomal degradation of insulin in vitro, was without apparent effect on the level of insulin receptors present in endosomes but induced a more prolonged tyrosine autophosphorylation of the insulin receptor ␤-subunit. The concentration of pepstatin A required to demonstrate this same phenomenon in vitro was in the order of 1 g/ml and induced a complete inhibitory effect. The modest effect of pepstatin A observed in vivo probably reflects its low degree of cell and organelle penetrance (59, 60) and also its inability to affect the dissociation of internalized insulin from its endosomal receptor, which attenuates any further liganddriven receptor re-phosphorylation (3). Moreover, after intravenous administration in rats, pepstatin A is rapidly cleared from the blood by the kidneys (61) , confirming that it requires very high concentrations to be effective in vivo (60) . Consequently, because cells are rather impermeable to pepstatin A, it was necessary to treat rats with high concentrations (Ͼ1 mg) in the presence of Me 2 SO to obtain effective intracellular concentrations. The development of specific and potent inhibitors of CD activity will greatly advance the elucidation of the function of the endosomal proteolysis of internalized insulin.
Some studies point out that the defects in the metabolism of intracellular insulin observed in non-insulin-dependent diabetes mellitus could be localized within the endosomal apparatus and are caused mainly by a defective acidification of its interior (62, 63) . Studies are under way to determine whether the pathological decrease in endosomal proteolysis of insulin observed in non-insulin-dependent diabetes mellitus may also be caused by alterations in the endosomal targeting or activity of the pepstatin A-sensitive CD activity.
